Pulse Biosciences Ownership
| PLSE Stock | USD 17.80 0.39 2.24% |
Shares in Circulation | First Issued 2015-03-31 | Previous Quarter 57.2 M | Current Value 61.1 M | Avarage Shares Outstanding 25.5 M | Quarterly Volatility 15.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Pulse |
Pulse Stock Ownership Analysis
About 72.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 0.82. Pulse Biosciences had not issued any dividends in recent years. Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California. Pulse Biosciences operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 142 people. To find out more about Pulse Biosciences contact Kevin Danahy at 510 906 4600 or learn more at https://www.pulsebiosciences.com.Besides selling stocks to institutional investors, Pulse Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Pulse Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Pulse Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Pulse Biosciences Quarterly Liabilities And Stockholders Equity |
|
Pulse Biosciences Insider Trades History
About 72.0% of Pulse Biosciences are currently held by insiders. Unlike Pulse Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Pulse Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Pulse Biosciences' insider trades
Pulse Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Pulse Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Pulse Biosciences backward and forwards among themselves. Pulse Biosciences' institutional investor refers to the entity that pools money to purchase Pulse Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Westside Investment Management, Inc. | 2024-09-30 | 55 K | Bank Of New York Mellon Corp | 2024-09-30 | 40.3 K | Spotlight Asset Group, Inc. | 2024-06-30 | 40.3 K | Swiss National Bank | 2024-09-30 | 35.9 K | Goldman Sachs Group Inc | 2024-09-30 | 35.7 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 33.5 K | Barclays Plc | 2024-09-30 | 30.3 K | Tiaa Trust National Association | 2024-09-30 | 27.3 K | Rhumbline Advisers | 2024-09-30 | 25.8 K | Blackrock Inc | 2024-06-30 | 1.1 M | Vanguard Group Inc | 2024-09-30 | 995.8 K |
Pulse Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pulse Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pulse Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Pulse Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Pulse Biosciences Outstanding Bonds
Pulse Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Pulse Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Pulse bonds can be classified according to their maturity, which is the date when Pulse Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| PulteGroup 6 percent Corp BondUS745867AT82 | View | |
| PulteGroup 55 percent Corp BondUS745867AW12 | View | |
| PulteGroup 5 percent Corp BondUS745867AX94 | View |
Pulse Biosciences Corporate Filings
F4 | 20th of December 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 19th of December 2024 Other Reports | ViewVerify | |
8K | 6th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 19th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulse Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulse Biosciences. If investors know Pulse will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulse Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Pulse Biosciences is measured differently than its book value, which is the value of Pulse that is recorded on the company's balance sheet. Investors also form their own opinion of Pulse Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Pulse Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulse Biosciences' market value can be influenced by many factors that don't directly affect Pulse Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pulse Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulse Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulse Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.